ArticleEuropean journal of nuclear medicine and molecular imaging2018
Prognostic value of [
Article in European journal of nuclear medicine and molecular imaging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 26 citations in OpenAlex.
- Review
- Coefficient of variation and texture analysis of 18F-FDG PET/CT images for the prediction of outcome in patients with multiple myeloma.Annals of hematology · 2024Article
- Recent advances in imaging and artificial intelligence (AI) for quantitative assessment of multiple myeloma.American journal of nuclear medicine and molecular imaging · 2024Review
- New Developments in Myeloma Treatment and Response Assessment.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- Allogeneic Hematopoietic Cell Transplantation Induces Vessel Wall Inflammation in Large Arteries.JACC. Advances · 2023Article
- PET/CT Evaluation of the Effect of Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of T-Cell Lymphoblastic Lymphoma.Contrast media & molecular imaging · 2022Review
- Reduced splenic uptake onTheranostics · 2022Article
- Metabolic Volume Measurements in Multiple Myeloma.Metabolites · 2021Review
- Comparison between tumour metabolism derived fromQuantitative imaging in medicine and surgery · 2021Article
- Positron Emission Tomography (PET) Imaging of Multiple Myeloma in a Post-Treatment Setting.Diagnostics (Basel, Switzerland) · 2021Review
- The value ofOncology letters · 2020Article
- Article
- Article
- Article
- Interest of Pet Imaging in Multiple Myeloma.Frontiers in medicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 2 countries.
Funding
Abstract
purposeDespite improved treatment options, multiple myeloma (MM) remains an incurable disease. The aim of this study was to investigate the prognostic value of positron emission tomography/computed tomography (PET/CT) using
methodsIn this retrospective analysis, we evaluated [
resultsPET/CT negativity -prior to or following allo-HCT- was a favorable prognostic factor for progression-free and overall survival (both, PFS and OS: pre-HSCT p < 0.001, post-HCT p < 0.005). High FDG-uptake (SUV
conclusion[
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.